At only one tenth the size of traditional antibodies new VNAR biologics could be used to both treat and protect against SARSCoV-2 infections January 25th 2021: Aberdeen, Scotland: Elasmogen Ltd, the pioneering biopharmaceutical company leading the development of VNAR and soloMERTM biologics, today announces a significant breakthrough in the identification of next-generation protein-based drugs potentially […]
Author: Karim Mahmoud
Elasmogen announces grants of 2 new VNAR and soloMER patent families | 09.12.2020
New grants across multiple territories cover the use of humanised or de-immunised VNARs for therapeutic applications December 9th 2020: Aberdeen, Scotland: Elasmogen Ltd, the biopharmaceutical company leading the development of soloMERTM biologics, today announces a significant development in its comprehensive intellectual property position as two new patent families go to grant in multiple territories. These […]
Elasmogen wins two grants worth £374,000 | 08.07.2020
New awards for COVID-19 and oncology programs support re-opening of labs in Aberdeen Aberdeen, UK, 8th July 2020: Aberdeen drug discovery pioneer, Elasmogen Ltd has won two new grants worth £374,000 to support programs for COVID-19 and oncology. In April 2020 Elasmogen secured £143,000 from Scottish Government to use their drug discovery platform to accelerate […]
Intract Pharma and Elasmogen Ltd announce collaboration to discover and develop novel, orally-delivered protein therapeutics | 05.05.2020
Intract Pharma Limited London, UK (“Intract”), and Elasmogen Limited, Aberdeen, Scotland (“Elasmogen”) have announced an agreement to collaborate and develop novel orally-delivered protein therapeutics (biologics), incorporating proprietary technologies developed by each of the partners. The collaboration combines Elasmogen’s soloMER™ technology, small (11 kDa) single-chain binding domains that can be rapidly re-formatted to generate super-neutralizers (bivalent, […]
Elasmogen Ltd to deploy their soloMER technology platform to develop tools to combat COVID-19 | 29.04.2020
29th April 2020; Elasmogen Limited, Aberdeen, Scotland (“Elasmogen”) are to collaborate with the University of Aberdeen as a partner on a Scottish Government research award of almost £1 M to tackle COVID-19. Current diagnostic testing for COVID-19 so called RT-PCR for infectious agents, whilst accurate is complex to perform, suited to centralised laboratories, takes […]
Elasmogen featured in Biotechnology and Biological Sciences Research Council Spinout report | 26.02.2020
Elasmogen has been featured in BBSRC’s report highlighting a few spinout companies that exemplify BBSRC investments in research.
Elasmogen nominated for Innovative Collaboration award with Almac Discovery | 24.01.2020
Elasmogen has been nominated for a Life Science Award with Almac Discovery in the Innovative Collaboration category. The finalists in the Innovative Collaboration award, sponsored by @MarksClerkScot are announced! They are @ElasmogenLtd , @iCAIRD_Scot , and @MedtronicUK . Find out who wins at #ScotLiSciAwards on 19 March – tickets available at https://t.co/z5f5tnBLNS pic.twitter.com/9Q7SOYezme — LifeScienceAwardScot […]
Elasmogen Secures £2 M Funding | 13.01.2020
Funding from Deepbridge Capital will support development of next generation biologics January 10th 2020: Aberdeen, Scotland: Elasmogen Ltd, the biopharmaceutical company leading the development of soloMERTM biologics, today announced it has secured follow-on equity investment from Deepbridge Capital totalling £2 M, taking Deepbridge’s total investment in Elasmogen to £3.15 M. The funding will be used […]
Elasmogen technology featured in The Times news | 13.12.2019
We are delighted that The Times has featured Elasmogen in an article titled ‘Ruthless killers? Shark antibodies are latest weapon in fight against cancer‘.
Elasmogen featured in CONVERGE podcast | 19.11.2019
Elasmogen’s CEO, Caroline Barelle is featured in Converge’s podcast where she discusses her business journey.